Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ: QNTM) announced completion of oral dosing in both 180-day repeated-dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS). These chronic studies are described as supporting an Investigational New Drug (IND) application with the US FDA and informing the design of a Phase 2 trial in people with multiple sclerosis (MS). Company executives said study completion advances the Lucid-MS development program and moves the program closer to initiating a Phase 2 trial targeting prevention of disease progression and inhibition of demyelination in MS.
Quantum BioPharma (NASDAQ: QNTM) closed a non-brokered private placement on December 10, 2025, issuing 30 Class A multiple voting shares at $25 per share for gross proceeds of $750. Two related parties — Xorax Family Trust and Fortius Research and Trading — each bought 15 Class A shares, triggering MI 61-101 and early warning disclosures under NI 62-103.
Following the offering, Xorax's voting rights rose to 37.66% and Fortius' to 37.63%. The company also terminated its at-the-market sales agreement with H.C. Wainwright effective Dec 20, 2025, and settled $260,000 of debt by issuing 17,626 Class B subordinate voting shares at a deemed price of $14.75 per share.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 30, 2025 at 4:15 PM EST (1:15 PM PST) to discuss a Regulation D 506(c) offering targeting US$5.0 million to expand distribution of unbuzzd, a beverage the company says accelerates alcohol metabolism and reduces hangover symptoms. The release states that Quantum shareholders will not be diluted by this offering and that the offering is for accredited investors only. Webinar speakers include Unbuzzd CEO John Duffy, Medical Director Dr. Eric Hoskins, Advisor Jason Sawyer, and Board Co-Chair Gerry David. A replay is available on request via investor@unbuzzd.com.
Summary not available.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
